ASA plus Clopidogrel — Competitive Intelligence Brief

ASA plus Clopidogrel (ASA plus Clopidogrel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual antiplatelet agent. Area: Cardiovascular.

marketed Dual antiplatelet agent COX-1 (aspirin); P2Y12 receptor (clopidogrel) Cardiovascular Small molecule

Target snapshot

ASA plus Clopidogrel (ASA plus Clopidogrel) — Texas Cardiac Arrhythmia Research Foundation. ASA and clopidogrel together inhibit platelet aggregation through different pathways to reduce thrombotic events.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ASA plus Clopidogrel TARGET	ASA plus Clopidogrel	Texas Cardiac Arrhythmia Research Foundation	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (clopidogrel)
Ticagrelor plus aspirin	Ticagrelor plus aspirin	Fujian Medical University	marketed	Dual antiplatelet agent combination	P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin)
Acetylsalicylic Acid + clopidogrel	Acetylsalicylic Acid + clopidogrel	Hospital Universitari Vall d'Hebron Research Institute	marketed	Dual antiplatelet agent	Cyclooxygenase-1 (COX-1) and P2Y12 receptor
ticagrelor + ASA	ticagrelor + ASA	Peking University Third Hospital	marketed	Dual antiplatelet agent	P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin)
clopidogrel bisulfate + aspirin	clopidogrel bisulfate + aspirin	Seoul National University Hospital	marketed	Dual antiplatelet agent	P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin)
Vorapaxar and Clopidogrel	Vorapaxar and Clopidogrel	Inova Health Care Services	marketed	Dual antiplatelet agent	PAR-1 (vorapaxar) and P2Y12 receptor (clopidogrel)
Active Comparator: Aspirin+Clopidogrel	Active Comparator: Aspirin+Clopidogrel	Chinese Academy of Medical Sciences, Fuwai Hospital	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (clopidogrel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual antiplatelet agent class)

1. Seoul National University Hospital · 3 drugs in this class
2. Chinese Academy of Medical Sciences, Fuwai Hospital · 1 drug in this class
3. Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
4. Inova Health Care Services · 1 drug in this class
5. Peking University Third Hospital · 1 drug in this class
6. Rigshospitalet, Denmark · 1 drug in this class
7. Texas Cardiac Arrhythmia Research Foundation · 1 drug in this class
8. The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · 1 drug in this class
9. The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class
10. University of Athens · 1 drug in this class